Abivax Shares Close at 122.40 Euros, Slightly Down After Annual Surge

Market Dynamics and Technical Indicators

Trading volumes remained low with only 0.21% of the capital traded, indicating a cautious market at the end of the year. This slight correction follows a week of 21.2% increase, bringing the quarterly performance to 72.4% and the annual growth to a stratospheric level of 1,619%. The stock touched its resistance level at 122 euros, a threshold it failed to consistently surpass during this session. Technically, an RSI at 70 points suggests that the stock is in an overbought zone, indicating a possible pause after the recent strong upward momentum. The price is significantly above its moving averages, with a gap of 48.64 euros from the MM200, confirming the strength of the underlying trend that began with the positive results from the Phase III clinical trials published in July 2025.

Recent Developments and Market Speculations

The recent context is marked by two major catalysts. On one hand, the company officially joined the Nasdaq Biotechnology Index on December 22, 2025, enhancing its visibility among international institutional investors. On the other hand, speculations continue about a potential acquisition by the American pharmaceutical group Eli Lilly, fueled by media reports mentioning contacts with French authorities. Abivax maintains a no-comment policy regarding these market rumors. From the analysts' perspective, recent recommendations are positive with target prices ranging from 131 to 142 euros, representing a significant upside potential compared to the current level. These valuations reflect the commercial prospects of obefazimod, the company's leading drug candidate in the treatment of ulcerative colitis, with results from the 44-week maintenance trial expected in the second quarter of 2026. The company's cash reserves of 589.7 million euros ensure financial autonomy until the fourth quarter of 2027.